Published in Cancer Res on September 01, 1997
The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci U S A (2001) 1.78
Deletion of histidine triad nucleotide-binding protein 1/PKC-interacting protein in mice enhances cell growth and carcinogenesis. Proc Natl Acad Sci U S A (2003) 1.55
High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol (2001) 1.36
Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. Proc Natl Acad Sci U S A (1997) 1.24
The FHIT gene product: tumor suppressor and genome "caretaker". Cell Mol Life Sci (2014) 1.01
Deletion at fragile sites is a common and early event in Barrett's esophagus. Mol Cancer Res (2010) 0.89
Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors. Breast Cancer Res Treat (2010) 0.86
Fragile histidine triad protein: structure, function, and its association with tumorogenesis. J Cancer Res Clin Oncol (2009) 0.85
Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma. Am J Pathol (2002) 0.85
Quantitative assessment of the diagnostic role of FHIT promoter methylation in non-small cell lung cancer. Oncotarget (2016) 0.78
Multiple Patterns of FHIT Gene Homozygous Deletion in Egyptian Breast Cancer Patients. Int J Breast Cancer (2011) 0.78
Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil. J Clin Pathol (2004) 0.77
HIT family genes: FHIT but not PKCI-1/HINT produces altered transcripts in colorectal cancer. Br J Cancer (1999) 0.76
FHIT gene sequence variants and reduced Fhit protein expression in glioblastoma multiforme. Cell Mol Neurobiol (2009) 0.76
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res (1987) 10.80
PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature (1993) 8.83
p53: a frequent target for genetic abnormalities in lung cancer. Science (1989) 7.51
Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature (1984) 6.23
Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood (1980) 6.17
Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res (1985) 5.02
L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature (1985) 4.66
Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature (1985) 4.47
Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (1988) 4.26
BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res (1999) 4.16
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst (2001) 4.14
Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci U S A (1990) 4.06
Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell (1998) 3.86
Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin (2001) 3.65
Continuous, clonal, insulin- and somatostatin-secreting cell lines established from a transplantable rat islet cell tumor. Proc Natl Acad Sci U S A (1980) 3.39
NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl (1996) 3.24
Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer (1998) 3.12
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A (1990) 3.03
Molecular genetics of small cell lung carcinoma. Semin Oncol (2001) 3.02
p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J (1992) 2.90
Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst (1997) 2.83
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene (2008) 2.83
Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res (2001) 2.80
NCI series of cell lines: an historical perspective. J Cell Biochem Suppl (1996) 2.75
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res (1998) 2.72
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene (1992) 2.64
Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet (2000) 2.60
Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature (1987) 2.59
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res (1987) 2.56
Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res (2001) 2.50
Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst (2000) 2.45
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol (2007) 2.43
Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest (1998) 2.39
Chemotherapy for non-small cell lung cancer. BMJ (1995) 2.39
Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest (1997) 2.30
Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene (2007) 2.27
Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res (2000) 2.24
Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. Environ Health Perspect (1998) 2.22
Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene (2001) 2.22
Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst (1995) 2.18
Conservation of autosomal gene synteny groups in mouse and man. Nature (1978) 2.18
Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene (2006) 2.14
Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene. Proc Natl Acad Sci U S A (1989) 2.13
Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res (1986) 2.12
Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res (1985) 2.12
Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res (1980) 2.10
Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene (1998) 2.10
Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res (1992) 2.09
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res (2000) 2.07
High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science (1981) 2.07
Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer. Chest (1993) 2.06
Identification of mouse chromosomes required for murine leukemia virus replication. Cell (1977) 2.05
Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst (1999) 2.03
Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci U S A (1990) 2.02
Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet (1982) 2.02
Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science (1982) 2.02
Gene mapping in Mus musculus by interspecific cell hybridization: assignment of the genes for tripeptidase-1 to chromosome 10, dipeptidase-2 to chromosome 18, acid phosphatase-1 to chromosome 12, and adenylate kinase-1 to chromosome 2. Cytogenet Cell Genet (1977) 1.98
Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci U S A (1986) 1.96